CD8A and non-small cell lung carcinoma: Meanwhile, in patients with NSCLC who were pretreated with nivolumab, PD-1+ CD8 T cells at baseline were more frequently detected in patients with clinical benefit (CB) than in those with non-response (NR) [27].